Effect of Anti-TNF Treatment on Mooren's Ulcer: A Case Series and Review of the Literature.

Annie Xia, Tina Dietrich-Ntoukas, Uwe Pleyer

Journal: Ocular immunology and inflammation 2023;31(4):675-681

PMID: 35050832

Full Text on Atypon View on PubMed

Abstract

PURPOSE

To report the efficacy of systemic anti-TNF agents in Mooren's ulcer.

DESIGN

Retrospective, consecutive case series.

METHODS

We report on clinical characteristics and outcome of five patients with Mooren's ulcer with anti-TNF treatment.

RESULTS

During a mean follow-up of 30 months, relief of symptoms and arrest of corneal melting were observed in all eyes. Systemic corticosteroid treatment could be discontinued or reduced to threshold levels. No patient experienced adverse effects on bDMARDs.

CONCLUSIONS

Our results suggest that bDMARDs are effective in Mooren's ulcer unresponsive to conventional treatment. This is in line with accumulating evidence in the current literature. Therefore, more targeted immunomodulatory approaches might be an effective first-line therapy in the future.

Address: Department of Ophthalmology, Charité - Universitaetsmedizin Berlin, corporate member of Freie Universitaet Berlin, Humboldt Universitaet zu Berlin, and Berlin Institute of Health, Berlin, Germany.

DOI: 10.1080/09273948.2021.2023581

Link outs

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.1080/09273948.2...

MeSH Terms: Humans, Tumor Necrosis Factor Inhibitors, Retrospective Studies, Ulcer, Corneal Ulcer, Corneal Transplantation